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Purpose: Notch signaling dysregulation is implicated in the development of pan-
creatic adenocarcinoma (PDAC). Tarextumab is a fully human IgG2 antibody that 
inhibits Notch2/3 receptors.
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1 |  INTRODUCTION
Patients with pancreatic ductal adenocarcinoma (PDAC) face 
a challenging prognosis. More than half of those at diagnosis 
have stage IV disease for which the 5‐year overall survival is 
3%.1 Current combination cytotoxic therapies for metastatic 
PDAC have shown real but modest overall survival impact.2,3 
A potential explanation for either de novo or acquired treat-
ment resistance is the presence of cancer stem cells (CSCs), 
cells that possess the capacity for self‐renewal, differentiation 
into multiple lineages, and the ability to proliferate exten-
sively.4 CSCs have been shown to be more resistant to chemo-
therapy and radiotherapy than remaining epithelial malignant 
cells, persisting after therapy to drive tumor growth.5,6 The 
abnormal expression of the Notch pathway, a key regulator 
of PDAC CSCs, has been linked to disease progression and 
chemotherapy resistance in metastatic PDAC.7-11
Tarextumab (OMP‐59R5) is a fully human IgG2 anti-
body against the Notch2 and Notch3 receptors.12 Preclinical 
studies using pancreatic xenograft models have found that 
treatment with the combination of tarextumab, gemcitabine, 
and nab‐paclitaxel induced tumor regression, decreased 
CSC frequency, and delayed tumor progression compared to 
treatment with cytotoxic therapy alone.12 Tarextumab also 
downregulated Rg5, a marker of developing pericytes, and 
facilitated pericyte recruitment to endothelial cells. Loss of 
Rg5 has been reported to reduce tumor hypoxia and to nor-
malize vasculature.13 Consequently, tarextumab may enhance 
chemotherapy sensitivity by lowering CSC frequency and re-
ducing tumor hypoxia. Higher Notch3 gene expression lev-
els in these pancreatic tumor models were also found to be 
associated with increased sensitivity to the combination of 
tarextumab and gemcitabine. Based on the preclinical data, 
our hypothesis was that PDAC patients with higher levels 
of Notch3 gene expression in tumor cells would have an en-
hanced potential for therapeutic benefit from the addition of 
tarextumab to standard therapy.
In a phase Ib study of N  =  38 patients with previously 
untreated metastatic PDAC, tarextumab was evaluated in 
combination with nab‐paclitaxel and gemcitabine. The rec-
ommended phase 2 dose (RP2D) was determined to be 15 mg/
kg with standard doses of the cytotoxic agents. Diarrhea, 
fatigue, and anemia were the most common tarextumab‐re-
lated toxicities, and the events were mostly Grade 1 or 2. 
Funding information
This work was funded in part by: National 
Cancer Institute Cancer Center Core Grant 
No. P30‐17 CA008748.
Patients and Methods: Aphase 2, randomized, placebo‐controlled, multicenter trial 
evaluated the activity of tarextumab in combination with nab‐paclitaxel and gem-
citabine in patients with metastatic PDAC. Patients were stratified based on ECOG 
performance score and Ca 19‐9 level and randomized 1:1 to nab‐paclitaxel, gemcit-
abine with either tarextumab or placebo. Based on preclinical and phase Ib results 
suggesting a positive correlation between Notch3 gene expression and tarextumab 
anti‐tumor activity, patients were also divided into subgroups of low, intermediate, 
and high Notch3 gene expression. Primary endpoint was overall survival (OS) in all 
and in patients with the three Notch3 gene expression subgroups (≥25th, ≥50% and 
≥75% percentiles); secondary end points included progression‐free survival (PFS), 
12‐month OS, overall response rate (ORR), and safety and biomarker investigation.
Results: Median OS was 6.4 months in the tarextumab group vs 7.9 months in the 
placebo group (HR = 1.34 [95% CI = 0.95, 1.89], P = .0985). No difference observed 
in OS in the Notch3 gene expression subgroups. PFS in the tarextumab‐treated group 
(3.7 months) was significantly shorter compared with the placebo group (5.5 months) 
(hazard ratio was 1.43 [95% CI = 1.01, 2.01]; P = .04). Grade 3 diarrhea and throm-
bocytopenia were more common in the tarextumab group.
Conclusions: The addition of tarextumab to nab‐paclitaxel and gemcitabine did not 
improve OS, PFS, or ORR in first‐line metastatic PDAC, and PFS was specifically 
statistically worse in the tarextumab‐treated patients.
Clinical trial registry no: NCT01647828.
K E Y W O R D S
cancer stem cell, gemcitabine, nab‐paclitaxel, Notch 2/3 receptor inhibitor, Pancreatic cancer, tarextumab
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The overall response rate (CR + PR) was 29%.14 The median 
PFS and OS were 5.6 and 11.6 months, respectively. Patients 
with high expression of Notch3 were noted to have a PFS 
of 6.6  months and OS of 14.6  months. These results were 
deemed to compare favorably to reported PFS of 5.5 months 
and OS of 8.5 months in patients treated with gemcitabine 
and nab‐paclitaxel.3
Given the encouraging preclinical data, tolerable safety 
profile and the favorable PFS and OS results in the phase Ib 
study, a randomized phase II study comparing gemcitabine, 
nab‐paclitaxel with either tarextumab or placebo was initi-
ated in patients with previously untreated metastatic PDAC.
2 |  PATIENTS AND METHODS
2.1 | Study design and participants
This was a prospective, multicenter, randomized, double‐
blinded, placebo‐controlled phase II study in patients with 
untreated metastatic PDAC. Patients were randomized in 1:1 
ratio to receive either nab‐paclitaxel, gemcitabine and pla-
cebo or nab‐paclitaxel, gemcitabine and tarextumab (Figure 
1). Patients were divided into subsets based on Notch3 gene 
expression levels: Notch3 ≥ 25th percentile; Notch3 ≥ 50th 
percentile; Notch3 ≥ 75th percentile and all patients irrespec-
tive of Notch3 expression levels.
The primary endpoint of the study was overall survival 
(OS). Secondary endpoints included progression‐free sur-
vival (PFS), overall response rate (ORR), duration of re-
sponse (DOR), and CA19‐9 response.
Exploratory endpoints not reported herein included ex-
pression levels of epidermal growth factor receptor (EGFR), 
placental growth factor (PLGF), epithelial neutrophil‐ac-
tivating peptide (ENA 78), and other Notch‐related genes 
in the serum obtained at baseline and disease progression. 
Circulating tumor cells (CTCs), microRNAs, and circulating 
endothelial cells were also evaluated and will be reported 
separately.
Tumor assessments were assessed by RECIST version 
1.1 every 8 weeks using computed tomography or magnetic 
resonance imaging. Adverse events were graded using the 
National Cancer Institute Common Terminology Criteria for 
Adverse Events (CTCAE), version 4.02.15
Individuals (age > 18 years) with newly diagnosed, patho-
logically confirmed stage IV PDAC were enrolled. Eligibility 
criteria also included the presence of measurable disease 
according to RECIST version 1.1 and Eastern Cooperative 
Oncology Group (ECOG) performance status of 0 or 1. In 
additions, patients must have had formalin‐fixed, paraffin‐
embedded (FFPE) tumor tissue from metastatic sites, either 
archived or fresh core needle biopsied for Notch3 analysis at 
study entry.
Patients were required to have adequate organ func-
tion as defined by the following factors: absolute neu-
trophil count  ≥  1.5  ×  109/L, hemoglobin  ≥  9.0  g/dL, 
platelets  >  100  ×  109/L (have not received hematopoi-
etic growth factors, transfusion of blood and blood prod-
ucts  ≥  1  week prior to meeting the eligibility criteria), 
serum creatinine  ≤  1.5  mg/dL or calculated creatinine 
clearance  ≥  60  mL/min using the Cockcroft and Gault 
formula, bilirubin  ≤  1.5  ×  upper limit of normal (ULN), 
alanine aminotransferase (ALT) ≤ 3 × ULN, aspartate ami-
notransferase (AST)  ≤  3  ×  ULN), PT/INR  ≤  1.5  ×  ULN, 
aPTT ≤ 1.5 × ULN.
Patients were excluded for the following reasons: neu-
roendocrine tumors of the pancreas, brain metastases, prior 
therapy for stage IV PDAC, known human immunodefi-
ciency virus (HIV) infection, and major surgery <4  weeks 
F I G U R E  1  CONSORT diagram. ITT, intent to treat; nab‐p, nab‐paclitaxel; gem, gemcitabine
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prior to the first treatment. In addition, patients with serious 
or unstable concomitant systemic disorder incompatible with 
the study such as active infection, arterial thrombosis, and 
symptomatic pulmonary embolism were ineligible as were 
patients with any disorder that would significantly compro-
mise protocol compliance.
2.2 | Procedures
Nab‐paclitaxel 125  mg/m2 and gemcitabine 1000  mg/m2 
were administered on Days 1, 8, and 15 of every 28‐day 
cycle. Tarextumab or placebo was dosed at 15  mg/kg and 
administered on Days 1 and 15 of every 28‐day cycle. On 
days when tarextumab, nab‐paclitaxel and gemcitabine were 
given, tarextumab was administered first, then nab‐paclitaxel 
followed by gemcitabine. All agents were dosed until either 
disease progression or limiting toxicity occurred.
2.3 | Statistical analyses
Overall survival was the primary efficacy endpoint of this 
study and was defined as the time from randomization until 
death. The hazard in the control arm was 0.09 (median 
8 months) and hazard in the tarextumab arm 0.07 (median 
10  months). No treatment cross‐over was permitted in the 
study. The Kaplan‐Meier method was used to estimate both 
the survival curves and the median survival time. The 95% 
confidence intervals for median survival times and P‐value 
for treatment effect were generated using a stratified Cox 
proportional hazards model.
Final analysis of the study was planned to take place 
at the point when 104 progression events had occurred or 
10 months after the completion of enrollment, whichever oc-
curred first. This would ensure the study had 75% power to 
detect a hazard ratio of 0.67 (improvement in median PFS 
from 5.5 months to 8.2 months) and 80% power to detect a 
hazard ratio of 0.65 (improvement in median PFS from 5.5 
to 8.5 months) in the intention‐to‐treat (ITT) population with 
an associated total one‐sided type 1 error of 0.10. The data 
cutoff for the final analysis of survival was 6 months after the 
data cutoff for the final analysis of PFS or when 104 deaths 
have been observed, whichever occurred first.
Data were combined from all participating study sites for 
the analyses. All statistical testing was two‐sided and was 
performed at the 0.05 significance level. For continuous vari-
ables, descriptive statistics included the mean, SD, median, 
minimum, maximum, and the number of non‐missing val-
ues. For categorical variables, descriptive statistics included 
counts and percentages per category.
Notch3 gene expression analyses were conducted as 
follows; Notch3 gene expression correlated with efficacy 
in preclincial models. Ten primary patient derived pan-
creas cancer tumor xenografts were tested for efficacy in 
response to gemcitabine and tarextumab. Significant cor-
relation was found between the levels of tumor‐derived 
Notch3 and the efficacy of tarextumab. Responder tumors 
had higher levels of Notch3 compared to nonresponders 
when treated with the combination of chemotherapy and 
the antibody. Subsequently data from the phase Ib clinical 
trial evaluated 32 patient samples from 40 patients enrolled 
in 6 dose levels of tarextumab (ranging from 2.5 to 15 mg/
kg) with an 80% success rate for Notch3 gene expression 
adjudication. A trend was observed for the higher levels of 
Notch3 and increased time to tumor progression. Based on 
these collective preclinical and clinical data Notch3 gene 
expression subgroups (≥25th, ≥50% and ≥75% percentiles) 
were chosen to best differentiate outcome for the random-
ized phase II trial.
2.4 | Study oversight
The study was conducted in accordance with the Guideline 
for Good Clinical Practice, the ethical principles of the 
Declaration of Helsinki, and was approved by the institu-
tional review board at every site. All patients provided writ-
ten informed consent before enrollment.
3 |  RESULTS
3.1 | Patients
A pre‐planned interim efficacy and safety analysis was con-
ducted by an independent Data and Safety Monitoring Board 
(DSMB) on data from N = 172 patients treated by January 
2016 data cutoff date. From a safety standpoint, the DSMB 
identified no unexpected safety signals but noted worse RR 
and PFS in the tarextumab treatment group and a strong trend 
toward lack of OS benefit in the tarextumab treatment group, 
irrespective of Notch3 expression levels. The study was sub-
sequently terminated in March 2016 by the sponsor due to 
futility.
One hundred and seventy‐seven patients were enrolled 
in the study in 25 centers throughout the United States from 
July 2014 to March 2016 (Table 1). Fifty‐nine per cent 
were male, the median age was 66 years (range 34‐88) and 
the majority of patients were white. Eighty‐nine patients 
were assigned to the tarextumab arm and N  =  88 to the 
placebo arm.
The median duration of treatment was 2.6 months (range: 
0, 17.3) and 4.2 months (range: 0, 15.9) for patients in the tar-
extumab treatment group and the placebo group, respectively. 
The patients treated with tarextumab received a median of 
6.0 doses (range: 1, 37). The patients in the placebo group 
received a median of 9.0 doses (range: 1, 35). Two placebo 
patients were lost to follow‐up and two tarextumab‐treated 
patients withdrew consent.
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3.2 | Efficacy
The median OS was 6.4 months (95% CI = 4.17, 8.2) in the 
tarextumab group compared with 7.9 months (95% CI = 6.18, 
10.52) in the placebo group (Figure 2A). No statistically signifi-
cant difference was observed in OS in the tarextumab treatment 
group compared with the placebo group (HR  =  1.34 [95% 
CI = 0.95, 1.89], P = .09). No statistically significant difference 
was observed in OS in patients with Notch3 ≥ 25th percentile, 
Notch3 ≥ 50th percentile, or Notch3 ≥ 75th percentile (Figure 3).
The median PFS was 3.7 months (95% CI = 1.94, 4.21) in 
the tarextumab group and 5.5 months (95% CI = 3.72, 5.79) 
  Tarextumab (n = 89) Placebo (n = 88) Total (n = 177)
Median age, years 
(range)
66 (34‐88) 66 (40‐82) 66 (34‐88)
Sex, n (%)
Male 50 (56%) 54 (61%) 104 (59%)
Female 39 (44%) 34 (39%) 73 (41%)
ECOG score, n (%)
0 34 (38%) 34 (39%) 68 (38%)
1 55 (62%) 54 (61%) 109 (62%)
CA 19‐9 Levels
0 to ULN 19 (21%) 18 (20%) 37 (21%)
>ULN to 59xULN 24 (27%) 26 (30%) 50 (28%)
≥59xULN 46 (52%) 44 (50%) 90 (51%)
Primary pancreatic tumor location, n (%)a
Head 39 (44%) 37 (42%) 76 (43%)
Body 34 (38%) 32 (36%) 66 (37%)
Tail 29 (33%) 32 (36%) 61 (35%)
Other 10 (11%) 9 (10%) 19 (11%)
Current site(s) of metastasis, n (%)a
Pancreas 86 (97%) 83 (94%) 169 (96%)
Liver 76 (85%) 78 (89%) 154 (87%)
Lungs 39 (44%) 31 (35%) 70 (40%)
Lymph nodes 34 (38%) 45 (51%) 79 (45%)
Other 23 (26%) 24 (27%) 47 (27%)
Kidney 3 (3%) 3 (3%) 6 (3%)
Bone 5 (6%) 5 (6%) 10 (6%)
Number of metastatic sites, n (%)
1 1 (1%) 1 (1%) 2 (1%)
2 28 (32%) 27 (31%) 55 (31%)
≥3 60 (67%) 59 (67%) 119 (67%)
Prior surgery, n (%)
Yes 6 (7%) 6 (7%) 12 (7%)
No 83 (93%) 82 (93%) 165 (93%)
Prior radiotherapy, n (%)
Yes 2 (2%) 1 (1%) 3 (2%)
No 87 (98%) 87 (99%) 174 (98%)
Prior systemic therapy, n (%)b
Yes 1 (1%) 2 (2%) 3 (2%)
No 88 (99%) 86 (98%) 174 (98%)
aPatients may be included in more than one site of disease. Percentage may add up to more than 100%. 
bThese patients received prior systemic therapy as adjuvant therapy. 
T A B L E  1  Patient baseline 
characteristics
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F I G U R E  2  (A) Overall survival 
and (B) Progression‐free survival in the 
intent‐to‐treat population. Red, tarextumab 
with gemcitabine and nab‐paclitaxel; black, 
placebo with gemcitabine and nab‐paclitaxel
F I G U R E  3  Kaplan‐Meier analysis of overall survival in the intent‐to‐treat population divided by percentile. (A) OS for patients with ≥25th 
percentile Notch3 expression, (B) OS for patients with ≥50th percentile Notch3 expression, (C) OS for patients with ≥75th percentile Notch3 
expression. Red, tarextumab with gemcitabine and nab‐paclitaxel; black, placebo with gemcitabine and nab‐paclitaxel
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for the placebo group (Figure 2B). The PFS in the tarextumab 
treatment group was significantly shorter compared with the 
placebo group (HR 1.43 [95% CI = 1.01, 2.01]; P = .04). No 
statistically significant difference was observed in PFS in pa-
tients with Notch3 ≥ 25th percentile, Notch3 ≥ 50th percen-
tile, or Notch3 ≥ 75th percentile.
There was no significant difference in ORR (P =  .087) 
between the placebo‐treated group (31.8%; 95% CI = 22.3%, 
42.6%) compared with the tarextumab‐treated group (20.2%; 
95% CI = 12.4%, 30.1%) (Table 2). There was no significant 
difference in ORR between the Notch3 subgroups and pla-
cebo treatment groups.
The median duration of response (DOR) was 3.7 months 
(95% CI = 1.64, 5.52) in the tarextumab group and 3.6 months 
(95% CI = 2.14, 5.59) in the placebo group. No statistically 
significant difference was observed in the DOR between the 
two groups (P = .99).
CA19‐9 response was defined as a decrease of 50% or 
more in baseline CA19‐9 at any time post‐baseline. There 
was no statistically significant difference (P  =  .15) in re-
sponse between the placebo group (47.7%) and the tarex-
tumab‐treated group (37.1%).
3.3 | Safety
Treatment‐emergent adverse events (TEAEs) are summarized 
in Table 3. TEAEs were reported in 93% of the tarextumab 
group and 80% of the placebo group. There were no statisti-
cally significant differences in the rate of adverse events be-
tween the groups. Diarrhea (72% vs 40%), nausea (41% vs 
31%), and thrombocytopenia (49% vs 25%) were noted to 
occur more frequently in the tarextumab treatment group.
Fifty‐one (60%) patients in the placebo and N = 58 (66.7%) 
patients in the tarextumab group reported one or more serious 
AEs (SAE). In the tarextumab group, 22 (25.3%) patients had 
Grade 3 and 3 (3.4%) patients had Grade 4 SAE. Fourteen 
(16.1%) SAEs in the tarextumab‐treated group and 16 (18.8%) 
in the placebo‐treated group resulted in patient death; none of 
these SAEs were considered related to study drug treatment.
TEAEs in 8 tarextumab‐treated patients resulted in treat-
ment interruptions and 6 patients experienced tarextumab 
dose reductions due to TEAEs. TEAEs led to treatment dis-
continuation in 7 patients. A total of 126 (73.3%) patients 
died within 30  days of study discontinuation, 69 (79.3%) 
T A B L E  3  Treatment‐emergent adverse events related to 
tarextumab with incidence of at least 10% by system organ class




Diarrhea 34 (40%) 63 (72%)
Nausea 26 (31%) 36 (41%)
Vomiting 14 (16%) 19 (22%)
General disorders
Fatigue 50 (59%) 45 (52%)
Fever 10 (12%) 8 (9%)
Hematologic disorders
Thrombocytopenia 21 (25%) 43 (49%)
Anemia 22 (26%) 25 (29%)
Neutropenia 15 (18%) 8 (9%)
Metabolism and nutrition disorders
Decreased appetite 11 (13%) 15 (17%)
Dehydration 10 (12%) 8 (9%)
Nervous system disorders
Dysgeusia 8 (9%) 11 (13%)
Respiratory, thoracic and mediastinal disorders
Epistaxis 1 (1%) 9 (10%)
Patients with Grade 3 or 4 TEAEs
Diarrhea 2 (2%) 15 (17%)
Nausea 1 (1%) 6 (7%)
Fatigue 9 (11%) 13 (15%)
Thrombocytopenia 6 (7%) 19 (22%)
Anemia 8 (9%) 14 (16%)






Overall response rate 18 (20%) 28 (32%)
Partial response 18 (20%) 28 (32%)
Stable disease 31 (35%) 36 (41%)
Progression of disease 
(POD)
21 (24%) 6 (7%)
Not Evaluable — 1 (1%)
Clinical POD (no fol-
low up imaging)
19 (21%) 17 (19%)
aPer RECIST v1.1 
T A B L E  2  Treatment response
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tarextumab‐treated patients and 57 (67.1%) placebo‐treated 
patients. None of the deaths were adjudicated as related to 
tarextumab.
4 |  DISCUSSION
Strong preclinical evidence with patient‐derived xenograft 
(PDX) pancreatic models and phase Ib trial data provided a 
compelling rationale for the clinical evaluation of Notch sign-
aling inhibition combined with gemcitabine and nab‐paclitaxel 
therapy in a randomized phase 2 trial.12 Tarextumab treatment 
in combination with gemcitabine in PDX models resulted in 
decreased Notch2 and Notch3 expression, increased apoptotic 
cell death, decreased tumor cell density, and increased vessel 
perfusion and decreased hypoxia intratumorally.12 Mean gene 
expression levels of Notch3 were noted to be significantly 
higher in responders compared to nonresponders, suggesting 
that higher Notch3 expression may be a useful biomarker of 
sensitivity to tarextumab treatment.
In view of the encouraging preclinical findings, early 
phase trials were initiated in metastatic PDAC and extensive 
stage small cell lung cancer. Results from both phase Ib clin-
ical trials were potentially promising, with reported response 
rates of 84% and 74% in the small cell lung and pancreatic 
cancer trials, respectively.14,16 Analysis of the phase Ib clini-
cal trial in PDAC demonstrated a PFS of 5.6 months and OS 
of 11.6 months in patients treated with tarextumab in combi-
nation with gemcitabine and nab‐paclitaxel. In the subgroup 
of patients with high Notch3 expression, PFS and OS were 
6.6 and 14.6 months, respectively.
However, both the small cell lung cancer and PDAC 
randomized phase II clinical trials failed to meet their pri-
mary objective of a statistically significant improvement 
in OS. In the trial reported herein in PDAC, the PFS for 
the tarextumab treatment group was shorter compared to 
the placebo group. Analysis of the Notch3 subgroups also 
found no difference in PFS and OS between the subgroups. 
To summarize, we found no benefit in adding tarextumab 
to standard cytotoxic therapy in this randomized phase II 
trial of patients with metastatic PDAC, with a statistically 
significant decrease in median PFS and concerning neg-
ative trend in OS for some pre‐specified subgroups. It is 
possible that some of the worse outcome was attributed to 
higher toxicity in the tarextumab vs placebo‐treated pa-
tients resulting in a lower median treatment duration (2.6 
vs 4 months) and lower median number of treatment doses 
(6 vs 9 doses).
The discordances between the preclinical along with the 
early clinical development (phase Ib trial) results and the 
randomized phase II results are concerning and may be at-
tributed to differences in xenograft development, the patient 
population in the clinical trials, as well as the pleotropic 
nature of the Notch receptors and unrecognized contribu-
tions from the PDAC stroma. The human xenograft tumors 
used for the preclinical heterotopic implant model were 
obtained from stage III PDAC patients without metastases 
whereas the clinical trial treated metastatic PDAC patients. 
Compared to heterotopic models, orthotopic PDAC models, 
where tumor cells are implanted directly into the pancreas, 
retain a greater proportion of stromal components and de-
velop locoregional and distant metastases.17,18 Consequently, 
the preclinical results may have been more predictive of 
outcome for a localized PDAC population. In the phase Ib 
clinical trial, 11/38 patients (27.5%) patients had ≥3 meta-
static sites and 14 (35.0%) patients had two metastatic sites. 
In contrast, 67.2% of patients in the phase II clinical trial 
had ≥3 metastatic sites and 31.1% had two metastatic sites. 
Given the differences between the heterotopic PDX model 
and patient population, it is difficult to ascertain what roles 
Notch2 and Notch3 inhibition may play in promoting or in-
hibiting disease progression in a locoregional vs metastatic 
setting. An orthotopic or genetically engineered mouse mod-
els may promote better understanding in the future.
Notch1 inhibition has also been reported to cause 
an increase in liver metastases from neuroblastoma and 
breast cancer cells and may support early angiogenesis 
and growth of micrometastases within the liver.19 The pre-
clinical studies noted that tarextumab treatment alone and 
not combination therapy, decreased Notch1 intracellular 
domain levels in the xenograft OMP‐PN17 PDAC tumor.
This randomized phase II clinical trial also found no 
significant difference in PFS and OS between the low, in-
termediate, and high Notch3 subgroups. Further analyses of 
the exploratory biomarkers, including Notch‐related genes, 
CTCs, and circulating endothelial cells collected in this trial 
are ongoing and may be informative.
The exact role of Notch signaling in PDAC remains an 
area of significant debate, with some evidence supportive 
of an oncogenic role while other results have been more 
suggestive of its function as a tumor suppressor. Notch re-
ceptors and ligands have been found to be overexpressed in 
human and mouse PDAC cells, and have been implicated 
in the progression of pancreatic intraepithelial neoplasia 
(PanIN) lesions.10,20-22 Reports have differed, however, 
on which specific Notch receptor is central in the progres-
sion of PanIN and PDAC lesions, with results supporting 
Notch1,23 Notch2,21 and Notch3.24 Alternatively, loss of 
Notch1 in a KRAS‐driven PDAC mouse model resulted 
in increased tumor incidence and progression, implicating 
Notch signaling as a potential tumor suppressor.25
The discrete, collective, and relative contributions of 
the individual Notch receptors to tumor development in 
PDAC patients remain to be resolved. Further research 
into individual Notch inhibitors and agonists may help 
guide future clinical trials involving the Notch pathway 
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and cytotoxic chemotherapy. To additionally note, a ran-
domized phase II trial evaluating an anti‐Delta‐like ligand 
4 (DLL4) targeted agent (demcizumab), which is an in-
hibitor of the Notch pathway or placebo, combined with 
gemcitabine and nab‐paclitaxel observed no improvement 
in the primary endpoint of PFS compared to standard che-
motherapy and similarly there was no difference in overall 
survival (HR 1.02).26 The collective data suggest that tar-
geting the Notch pathway to date has little clinical utility 
in PDAC.
To sum up, the addition of tarextumab to gemcitabine 
and nab‐paclitaxel in untreated advanced PDAC did not im-
prove outcomes over standard therapy, and specifically PFS 
was statistically worse in the tarextumab‐treated group. This 
trial provides significant insights into the importance of pre-
clinical modeling in optimal and relevant model systems and 
underscores the need for randomized evaluation of experi-
mental agents.
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